Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
OwnerStephanie CORNEN, Laurent GAUTHIER +2inventors
InventorsStephanie CORNEN, Laurent GAUTHIER, Yannis MOREL, Olivier DEMARIA
Life of this patent
Estimating the term…
Abstract
Multi-specific proteins that bind to NKp46 and a cytokine receptor on NK cells, and optionally that further bind CD16A on NK cells, and that also bind to an antigen of interest (e.g. a cancer antigen) on a target cell (e.g. a cancer cell). The multi-specific proteins are capable of increasing NK cell cytotoxicity toward a target cell that expresses the antigen of interest (e.g., a cell that contributes to disease, a cancer cell).
Claims55
A multispecific protein which is capable of binding to an antigen of interest expressed by a target cell, and which is further capable of binding to NKp46, a cytokine receptor and optionally CD16A at the surface of an NK cell, and which multispecific protein is capable of potentiating NK cell cytotoxicity toward a target cell expressing an antigen of interest, the multispecific protein comprising:
- (a) an antigen binding domain (ABD) that binds to an antigen of interest;
- (b) an ABD that binds to a human NKp46 polypeptide;
- (c) an Fc domain, or a portion an Fc domain capable of binding FcRn;
- and
- (d) an ABD that binds a human cytokine receptor present on NK cells,
- wherein:
- the ABD that binds to a human NKp46 polypeptide is connected to the Fc domain, optionally via an Ig-derived or non-Ig-derived polypeptide linker, and wherein the the ABD that binds a human cytokine receptor is connected, via a polypeptide linker, to the ABD that binds to a human NKp46 polypeptide or to the Fc domain.
The protein of any one of the above claims, wherein the ABD that binds to a human NKp46 polypeptide and the ABD that binds a human cytokine receptor, and optionally the Fc domain, are configured to be capable of adopting a membrane-planar binding conformation such that the protein is capable of binding to NKp46 and the cytokine receptor, and optionally further CD16A, on the surface of an NK cell.
The protein of any one of the above claims, wherein the ABD that binds a human cytokine is connected to the ABD that binds to a human NKp46 polypeptide or the Fc domain by a linker peptide having 20 or less than 20 amino acid residues, optionally less than 15 amino acid residues, optionally less than 10 amino acid residues, optionally between 5 and 15 residues, optionally between 5 and 10 residues, optionally between 3 and 5 residues.
The protein of any one of the above claims, wherein the ABD that binds to a human NKp46 polypeptide is connected to the Fc domain by a linker peptide having 15 or less than 15 amino acid residues, optionally less than 10 amino acid residues, optionally between 4 and 15 residues, optionally between 3 and 10 residues, optionally between 4 and 5 residues.
The protein of any one of the above claims, wherein the ABD that binds to a human NKp46 polypeptide is connected to the Fc domain by an immunoglulin-derived linker peptide having 20 or less than 20 amino acid residues, optionally less than 15 amino acid residues, optionally between 4 and 15 residues, optionally between 4 and 10 residues, optionally between 3 and 5 residues, optionally wherein the linker comprises the amino acid sequence RTVA.
The protein of any one of the foregoing claims, wherein the ABD that binds NKp46 is interposed between the Fc domain and the ABD that binds the cytokine receptor.
The protein of any one of the foregoing claims, wherein each ABD comprises a VH and/or VL domain or fragment thereof, optionally wherein a VH and/or VL comprises three complementary determining regions (CDR1, CDR2 and CDR-3).
A protein comprising an ABD that binds to a human NKp46 polypeptide fused, optionally via a domain linker having 15 or less than 15 amino acid residues, to a cytokine that binds a receptor expressed at the surface of an NK cell.
The protein of claim of any one of the above claims, wherein the ABD that binds to a human NKp46 polypeptide comprises a VH and/or VL domain that binds to the D1/D2 junction of the human NKp46 polypeptide, and wherein the cytokine is a modified IL-2 polypeptide.
The protein of any one of the foregoing claims, wherein the protein is a heterodimer comprising a first and second polypeptide chain, or a heterotimer comprising a first, second and third polypeptide chain.
The protein of any one of the foregoing claims, comprising:
- (i) a first polypeptide chain comprising, from N- to C-terminal, a variable domain that binds NKp46, a human CH1 or CL constant domain, optionally a domain linker, and a wild-type or variant IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide, and
- (ii) a second polypeptide chain comprising, from N- to C-terminal, a variable domain that associates with the variable domain of (i) to form a NKp46-binding domain, and a human CH1 or CL constant domain;
- wherein one of the constant domains of (i) and (ii) is a CH1 and the other is a CL such that the constants domains of (i) and (ii) associate by CH1-CL dimerization.
The protein of any one of the foregoing claims, wherein the protein comprises a NKp46 ABD-cytokine unit having a domain arrangement:
- wherein:
- Va-2 and Vb-2 are each a VH domain or a VL domain, wherein one of Va-2 and Vb-2 is a VH and the other is a VL and wherein Va-2 and Vb-2 form a second ABD that binds NKp46;
- CH1 is a human immunoglobulin CH1 domain and CL is a human light chain constant domain;
- one of (CH1 or CL)a and (CH1 or CL)b is a CH1 and the other is a CL such that a (CH1/CL) pair is formed;
- L is a domain linker;
- and
- Cyt is a cytokine polypeptide or portion thereof that binds to a cytokine receptor present on NK cells, optionally wherein Cyt is a wild-type or variant human IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide.
The protein of any one of the foregoing claims, comprising:
- (a) (i) a first polypeptide chain comprising, from N- to C-terminal, an NKp46-binding domain or portion thereof comprising a variable domain comprising an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS:
- 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 or 236-313, a human CH1 or CL constant domain, a domain linker, and a wild-type or variant IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide comprising an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS:
- 404-439 or to a fragment thereof of at least 40, 50, 60, 80 or 100 contiguous amino acids thereof, and (ii) a second polypeptide chain comprising, from N- to C-terminal, a variable domain that associates with the variable domain of (i) to form a NKp46-binding domain wherein the variable domain comprises an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS:
- 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 or 314-403, and a human CH1 or CL constant domain;
- or
- (b) (i) a first polypeptide chain comprising, from N- to C-terminal, an NKp46-binding domain or portion thereof comprising a variable domain comprising an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS:
- 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 or 314-403, a human CH1 or CL constant domain, a domain linker, and a wild-type or variant IL-2, IL-15, IL-21, IL-7, IL-27, IL-12, IL-18, IFN-α or IFN-β polypeptide comprising an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS:
- 404-439 or to a fragment thereof of at least 40, 50, 60, 80 or 100 contiguous amino acids thereof, and
- (ii) a second polypeptide chain comprising, from N- to C-terminal, a variable domain that associates with the variable domain of (i) to form a NKp46-binding domain wherein the variable domain comprises an amino acid sequence at least 80%, 90%, 95%, 98% or 99% identical to an amino acid sequence of any of SEQ ID NOS:
- 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 or 236-313, and a human CH1 or CL constant domain.
The protein of any one of the foregoing claims, wherein the ABD that binds a cytokine receptor comprises an IL-2 polypeptide displaying reduced binding to CD25 compared to a wild-type human IL-2 polypeptide.
The protein of any one of the foregoing claims, wherein the protein or the ABD that binds to a human NKp46 polypeptide binds human NKp46 polypeptide with a KD of between 1 and 100 nM, as determined by SPR and/or wherein the protein or the cytokine binds the human cytokine receptor with a KD of between 10 nM and 1 μM, as determined by SPR.
The protein of any one of the above claims, wherein the multispecific polypeptide binds to a human Fcγ receptor, optionally CD16A, with an affinity for monovalent binding, as assessed by surface plasmon resonance, that is substantially equivalent to that of a full-length wild type human IgG1 antibody.
The protein of any one of the above claims, wherein the protein, immobilized on a surface, binds a soluble human CD16A polypeptide with a KD for monovalent binding that is no more than 2000 nM, optionally 1000-2000 nM, optionally 1100 or 1300 nM, as determined by surface plasmon resonance using Biacore.
The protein of any one of the foregoing claims, wherein the cytokine receptor is a receptor present at the surface of NK cells and that associates with the common γ-chain (γC;
- CD132), optionally further wherein wherein the cytokine receptor is the mid-affinity IL-2/IL-15Rβ receptor (CD122) or IL-21R (CD360), and optionally wherein the cytokine polypeptide is IL-2, IL-15 or IL-21.
The protein of any one of the above claims, wherein the ABD that binds to an antigen of interest comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH region comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity, to the amino acid sequence of SEQ ID NOS:
- 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154 or any of 236-313, and wherein the VL comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity, to the amino acid sequence of SEQ ID NOS:
- 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155 or any of 314-403.
The protein of any one of the above claims, wherein the ABD that binds to NKp46 comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH region comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity, to the amino acid sequence of SEQ ID NOS:
- 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 or any of 236-313, and wherein the VL comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity, to the amino acid sequence of SEQ ID NOS:
- 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 or any of 314-403.
The protein of any one of the above claims, wherein an Fc domain comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the Fc polypeptide of any of SEQ ID NOS:
- 160-165.
The protein of any one of the above claims, wherein a CH1 domain comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the CH1 polypeptide of any of SEQ ID NOS:
- 156.
The protein of any one of the above claims, wherein a CK or CL domain comprises an amino acid sequence having at least about 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the CK polypeptide of any of SEQ ID NOS:
- 156.
The protein of any one of the above claims, wherein the multispecific protein comprises:
- (a) an ABD that binds to the antigen of interest, wherein the ABD comprises an scFv or Fab,
- a. wherein the scFv comprises a VH comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS:
- 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154 and any of 236-313, a domain linker, and a VL comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS:
- 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155 and any of 314-403;
- and
- b. wherein the Fab comprises one VH comprising an amino acid sequence at least 90% identical to a selected from SEQ ID NOS:
- 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154 and any of 236-313, one VL comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS:
- 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155 and any of 314-403, one human CH1 domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
- 156 and one human CL domain comprising an amino acid sequence at least 90% identical to SEQ ID NOS:
- 159, wherein the VH is fused to one of the CH1 or CL domains, and the VL is fused to the other of the CH1 or CL domains,
- (b) an ABD that binds to a human NKp46 polypeptide, wherein the ABD comprises an scFv or Fab,
- a. wherein the scFv comprises a VH comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS:
- 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 and any of 236-313, a domain linker, and a VL comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS:
- 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 and any of 314-403;
- and
- b. wherein the Fab comprises one VH comprising an amino acid sequence at least 90% identical to a selected from SEQ ID NOS:
- 3, 5, 7, 9, 11, 13, 112, 113, 115, 116, 117, 119, 120, 121, 123, 124, 125, 127, 128, 129 and any of 236-313, one VL comprising an amino acid sequence at least 90% identical to a sequence selected from SEQ ID NOS:
- 4, 6, 8, 10, 12, 14, 114, 118, 122, 126, 130 and any of 314-403, one human CH1 domain comprising an amino acid sequence at least 90% identical to SEQ ID NO:
- 156 and one human CL domain comprising an amino acid sequence at least 90% identical to SEQ ID NOS:
- 159, wherein the VH is fused to one of the CH1 or CL domains, and the VL is fused to the other of the CH1 or CL domains,
- (c) a Fc domain dimer comprising a first and second Fc monomer wherein each Fc monomer comprises an amino acid sequence at least 80% or 90% identical to a sequence selected from SEQ ID NOS:
- 160-165;
- and
- (d) a cytokine polypeptide comprising an amino acid sequence at least 80% or 90% identical to a sequence selected from SEQ ID NOS:
- 404-439, or to a contiguous sequence of at least 40, 50, 60, 70, 80 or 100 amino acid residues thereof, fused, via a domain linker, to the C-terminus of one of the polypeptide chains of the multispecific protein.
The protein of any one of the above claims, wherein the target cell is a tumor cell.
The protein of any one of the above claims, wherein the antigen of interest is a cancer antigen.
The protein of any one of the above claims, wherein the multispecific protein competes for binding to a NKp46 polypeptide with a monoclonal antibody comprising the NKp46-1, NKp46-2, NKp46-3, NKp46-4, NKp46-6 or NKp46-9 VH and VL domains.
The protein of any one of the above claims, wherein the multispecific protein has decreased binding to a mutant NKp46 polypeptide selected from the group consisting of:
- (a) a mutant NKp46 polypeptide having a mutation at residues R101, V102, E104 and/or L105 compared to binding to the wild-type NKp46;
- (b) a mutant NKp46 polypeptide having a mutation any one or more of the residues K41, E42, E119, Y121 and/or Y194 compared to binding to the wild-type NKp46;
- and
- (c) a mutant NKp46 polypeptide having a mutation any one or more of the residues P132, E133, 1135, and/or S136 compared to binding to the wild-type NKp46.
The protein of any one of the above claims, wherein the antigen binding domain that binds NKp46 comprises:
- (a) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 3 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 4;
- (b) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 5 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 6;
- (c) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 7 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 8;
- (d) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 9 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 10;
- (e) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 11 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 12;
- or
- (f) a heavy chain comprising CDR 1, 2 and 3 of the heavy chain variable region of SEQ ID NO:
- 13 and a light chain comprising CDR 1, 2 and 3 of the light chain variable region of SEQ ID NO:
- 14.
A pharmaceutical composition comprising a multispecific protein of any one of the above claims, and a pharmaceutically acceptable carrier or adjuvant.
Dependencies are inferred from the claim text.